Therapeutic benefits of delayed lithium administration in the neonatal rat after cerebral hypoxia-ischemia

PLoS One. 2014 Sep 11;9(9):e107192. doi: 10.1371/journal.pone.0107192. eCollection 2014.

Abstract

Aim: We have previously shown that lithium treatment immediately after hypoxia-ischemia (HI) in neonatal rats affords both short- and long-term neuroprotection. The aim of this study was to evaluate possible therapeutic benefits when lithium treatment was delayed 5 days, a time point when most cell death is over.

Methods: Eight-day-old male rats were subjected to unilateral HI and 2 mmol/kg lithium chloride was injected intraperitoneally 5 days after the insult. Additional lithium injections of 1 mmol/kg were administered at 24 h intervals for the next 14 days. Brain injury was evaluated 12 weeks after HI. Serum cytokine measurements and behavioral analysis were performed before sacrificing the animals.

Results: Brain injury, as indicated by tissue loss, was reduced by 38.7%, from 276.5±27.4 mm3 in the vehicle-treated group to 169.3±25.9 mm3 in the lithium-treated group 12 weeks after HI (p<0.01). Motor hyperactivity and anxiety-like behavior after HI were normalized by lithium treatment. Lithium treatment increased neurogenesis in the dentate gyrus as indicated by doublecortin labeling. Serum cytokine levels, including IL-1α, IL-1β, and IL-6, were still elevated as late as 5 weeks after HI, but lithium treatment normalized these cytokine levels.

Conclusions: Delayed lithium treatment conferred long-term neuroprotection in neonatal rats after HI, and this opens a new avenue for future development of treatment strategies for neonatal brain injury that can be administered after the acute injury phase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Cytokines / blood
  • Doublecortin Protein
  • Hypoxia-Ischemia, Brain / blood
  • Hypoxia-Ischemia, Brain / drug therapy*
  • Hypoxia-Ischemia, Brain / pathology
  • Lithium Chloride / administration & dosage*
  • Male
  • Neurogenesis / drug effects
  • Neuroprotective Agents / administration & dosage*
  • Rats

Substances

  • Cytokines
  • Dcx protein, rat
  • Doublecortin Protein
  • Neuroprotective Agents
  • Lithium Chloride

Grants and funding

This work was supported by the Swedish Research Council (K2012-99X-21988-01-3), the National Natural Science Foundation of China (31271152), the Swedish Childhood Cancer Foundation (PROJ10/032), Swedish governmental grants to scientists working in health care (ALF)(ALFGBG-291241). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.